Historical IPO review | Reviewed 5 November 2026. This page covers a completed 2025 offering, not a currently open IPO. Its original Blogger address previously appeared in Google Search Console. The archival information is being reconstructed from publicly available records, not copied from an unavailable original article.
Corona Remedies completed its mainboard IPO in December 2025. This historical review brings together its price band, issue dates, bidding context and eventual stock-market debut so visitors searching for the old IPO can find information that remains useful after subscriptions have closed.
IPO dates, price band and key facts
| IPO opening | 8 December 2025 |
|---|---|
| IPO closing | 10 December 2025 |
| Price band | ₹1,008–₹1,062 |
| Issue price | ₹1,062 |
| Lot size | 14 shares |
| Issue size | Approximately ₹655.37 crore |
| Listing date | 15 December 2025 |
| Reported opening price | ₹1,470 |
Company and offer context
Corona Remedies is a branded pharmaceutical formulations company with products across therapeutic areas including women’s health, cardiology, diabetes, pain management and urology. The public offer was structured as an offer for sale. That matters when assessing use of proceeds: money from shares sold by existing shareholders does not directly increase the company’s operating cash.
IPO GMP versus the actual listing
An IPO grey market premium (GMP) is an unofficial quote before a stock lists. Quotes vary by market source and time, so a GMP cannot be treated as a guaranteed listing price. The comparison below uses reported exchange-opening prices where available, not unverified historical GMP numbers.
On the reported opening prices, Corona Remedies listed at ₹1,470 against an issue price of ₹1,062: a difference of ₹408 per share, or approximately 38.42%. An investor allotted a 14-share lot would have had an illustrative opening-price difference of ₹5,712 before costs and taxes. This is a listing-day arithmetic comparison, not a claim that anyone could necessarily sell at that exact price. The Economic Times IPO summary records approximately 137 times overall subscription, while figures on other platforms differ slightly in their category counts and calculation timestamps.
What investors should take away
After an IPO, investors should look beyond GMP to product concentration, compliance requirements, manufacturing quality, regulatory inspections, launch economics, marketing costs and research pipelines. Pharmaceutical growth narratives can be attractive, but the market price still depends on future earnings and valuation.
A listing-day return is not the same as a holding-period return. Prices can change quickly after trading starts, and historical opening performance does not predict how a different offering will perform. Always read the prospectus and assess valuation separately from market sentiment.
Related resources
Explore the full IPO GMP tracker, use our IPO profit calculator for illustrative scenarios, or return to WatchIPO GMP.
Sources and editorial notes
Information above was checked against the following sources. Where vendors show small differences in subscription counts or the first traded price, their reporting convention and timestamp may differ. Source links below let readers verify the underlying record.
This is informational historical coverage, not investment advice. Updated 5 November 2026.